Using a new treatment to prevent infections in second-degree burn wounds
Treating Second-Degree Burn Wound Infections with a Quorum Sensing Inhibitor
['FUNDING_SBIR_1'] · IONIC PHARMACEUTICALS · NIH-10916626
This study is testing a new gel that helps treat MRSA infections in burn wounds by blocking the bacteria's communication, making it easier for your body to fight the infection while being gentle and easy to use.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | IONIC PHARMACEUTICALS (nih funded) |
| Locations | 1 site (Watertown, UNITED STATES) |
| Trial ID | NIH-10916626 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to treating infections caused by methicillin-resistant Staphylococcus aureus (MRSA) in second-degree burn wounds. The treatment focuses on inhibiting quorum sensing, a communication method used by bacteria to coordinate their behavior and increase virulence. By applying a topical hydrogel containing a natural product called w-hydroxyemodin, the researchers aim to disrupt this communication and enhance the body's immune response. The hydrogel dressing is designed to be easy to apply and remove, minimizing pain and discomfort for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with second-degree burn wounds who are at risk of developing MRSA infections.
Not a fit: Patients with first-degree burns or those who do not have burn wounds may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for preventing infections in burn wounds, reducing complications and improving healing.
How similar studies have performed: While quorum sensing inhibition is a relatively novel approach, preliminary studies have shown promise in similar applications, indicating potential for success.
Where this research is happening
Watertown, UNITED STATES
- IONIC PHARMACEUTICALS — Watertown, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: COLBY, AARON HENRY — IONIC PHARMACEUTICALS
- Study coordinator: COLBY, AARON HENRY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.